In selected groups of patients with atrial fibrillation, ablation can lead to an improvement in symptoms and/or prognosis. To avoid complications, anticoagulation before, during and after ablation should be criteria-driven. There is a consensus that periprocedural oral anticoagulation (OAC) is generally recommended regardless of the thromboembolic risk. On the other hand, the longer-term continuation of OAC is controversial. The ALONE-AF study published in 2025 has provided new evidence in this regard.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Ischemic stroke: Are smaller or larger brain arteries affected?
Recent study findings on intravenous lysis therapy with fibrinolytic agents
- Interview
“On par with the gold standards for trauma”
- Psychology: Emotional Freedom Techniques (EFT)
Emotional Healing Through Tapping
- Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer?
Treat-to-Target – Consensus Recommendations for GC Tapering and the Use of DMARDs
- Psychedelic-assisted therapy
Current status of PAT
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Psoriasis and Obesity: Effects of Incretin-Based Therapies
Clinical trials shed light on the potential of semaglutide, liraglutide, and tirzepatide
- Eosinophils in the Blood in COPD